Gastroenterologie
a hepatologie

Komentář k článku „Účinnosť a bezpečnosť silymarínu u pacientov s chronickými chorobami pečene – multicentrická, prospektívna, otvorená klinická štúdia IMHOTEP“

Radan Brůha ^{Orcid.org  1}

+ Affiliation
¹ IV. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Holomáň J, Borecký P, Lietava J. Účinnost a bezpečnost silymarinu u pacientov s chronickými chorobami pečene – multicentrická, prospektívna, otvorená klinická štúdia IMHOTEP. Gastroent Hepatol 2014; 68(4): 346–355.
2. Rambaldi A, Jacobs BP, Iaquinto G et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic cochrane hepatobiliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100(11): 2583–2591.
3. Saller R, Brignoli R, Melzer J et al. An up­dated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008; 15(1): 9–20.
4. Berger J, Kowdley KV. Is silymarin hepatoprotective in alcoholic liver disease? J Clin Gastroenterol 2003; 37(4): 278–279.
5. Trappoliere M, Tuccillo C, Federico A et al. The treatment of NAFLD. Eur Rev Med Pharmacol Sci 2005; 9(5): 299–304.
6. Fried MW, Navarro VJ, Afdhal N et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 2012; 308(3): 274–282. doi: 10.1001/ jama.2012.8265.
7. Ferenci P, Scherzer TM, Kerschner H et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gas­troenterology 2008; 135(5): 1561–1567. doi: 10.1053/j.gastro.2008.07.072.
8. Marino Z, Crespo G, D'Amato M et al. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peritransplantation period. J Hepatol 2013; 58(3): 415–420. doi: 10.1016/j.jhep.2012.09.034.
9. Esser-Nobis K, Romero-Brey I, Gan­ten TM et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving non­structural protein 4B. Hepatology 2013; 57(3): 953–963. doi: 10.1002/hep.26260.
10. Freedman ND, Curto TM, Morishima C et al. Silymarin use and liver disease progression in the Hepatitis C antiviral long-term treatment against cirrhosis trial. Aliment Pharmacol Ther 2011; 33(1): 127–137. doi: 10.1111/j.1365-2036.2010.04503.x.
11. Velussi M, Cernigoi AM, De Monte A et al. Long-term (12 months) treatment with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26(4): 871–879.
12. Loguercio C, Federico A, Trappoliere M et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007; 52(9): 2387–2395.
13. Hajaghamohammadi AA, Ziaee A, Rafiei R. The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Hepat Mon 2008; 8(3): 191–195.
14. Hashemi S, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009; 9(4): 265–270.
15. Cacciapuoti F, Scognamiglio A, Palumbo R et al. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013; 5(3): 109–113. doi: 10.4254/wjh.v5.i3.109.
16. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9(1): 105–113.
17. Trinchet JC, Coste T, Lévy VG et al. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol 1989; 13(2): 120–124.
18. Bunout D, Hirsch S, Petermann M et al. Controlled study of the effect of silymarin on alcoholic liver disease. Rev Med Chil 1992; 120(12): 1370–1375.
19. Parés A, Planas R, Torres M et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28(4): 615–621.